| Year |
Citation |
Score |
| 2020 |
Ettl J, Im SA, Ro J, Masuda N, Colleoni M, Schnell P, Bananis E, Lu DR, Cristofanilli M, Rugo HS, Finn RS. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast Cancer Research : Bcr. 22: 27. PMID 32164785 DOI: 10.1186/S13058-020-01263-0 |
0.321 |
|
| 2019 |
Gelmon KA, Cristofanilli M, Rugo HS, DeMichele AM, Joy AA, Castrellon A, Sleckman B, Mori A, Theall KP, Lu DR, Huang X, Bananis E, Finn RS, Slamon DJ. Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. The Breast Journal. PMID 31448513 DOI: 10.1111/Tbj.13516 |
0.33 |
|
| 2018 |
Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Seminars in Arthritis and Rheumatism. PMID 30177460 DOI: 10.1016/J.Semarthrit.2018.07.006 |
0.317 |
|
| 2018 |
Strand V, Lee EB, Yazici Y, Dikranian A, Wilkinson B, Takiya L, Zang C, Bananis E, Bergman MJ. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clinical Rheumatology. PMID 29656373 DOI: 10.1007/S10067-018-4077-3 |
0.354 |
|
| 2018 |
Verma S, Im S, Ro J, Bondarenko I, Masuda N, Colleoni M, Verma S, Schnell P, Bananis E, Lu D(, Ettl J, Cristofanilli M, Rugo HS, Finn RS. Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2‒) advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies. Journal of Clinical Oncology. 36: 1060-1060. DOI: 10.1200/Jco.2018.36.15_Suppl.1060 |
0.304 |
|
| 2018 |
Gelmon K, Castrellon A, Joy A, Walshe J, Ettl J, Mukai H, Park I, Lu, Mori A, Bananis E, Diéras V, Finn R. Abstract P5-21-25: Efficacy and safety of palbociclib (PAL) + letrozole (LET) as first-line therapy in estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2 Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-21-25 |
0.321 |
|
| 2017 |
Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. The Journal of Rheumatology. PMID 29142036 DOI: 10.3899/Jrheum.170486 |
0.332 |
|
| 2017 |
Fleischmann RM, van der Heijde D, Gardiner PV, Szumski A, Marshall L, Bananis E. DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable. Rmd Open. 3: e000382. PMID 28255449 DOI: 10.1136/Rmdopen-2016-000382 |
0.337 |
|
| 2017 |
Aletaha D, Kivitz A, Valenzuela G, Tesser J, Hays S, Li H, Connell C, Bananis E, Soonasra A, Smolen J. THU0186 Magnitude and duration of early response with tofacitinib: post-hoc analysis of two phase 3, placebo-controlled studies Annals of the Rheumatic Diseases. 76: 272-273. DOI: 10.1136/Annrheumdis-2017-Eular.1556 |
0.316 |
|
| 2016 |
Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. Rmd Open. 2: e000232. PMID 27175296 DOI: 10.1136/Rmdopen-2015-000232 |
0.323 |
|
| 2016 |
Damjanov N, Shehhi WA, Huang F, Kotak S, Burgos-Vargas R, Shirazy K, Bananis E, Szumski A, Llamado LJ, Mahgoub E. Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia. Rheumatology International. PMID 26968844 DOI: 10.1007/S00296-016-3452-0 |
0.327 |
|
| 2016 |
van Vollenhoven R, Cohen S, Mendelsohn A, Bananis E, Fan H, Takiya L, Fleischmann R. AB0398 Efficacy of Adalimumab and Tofacitinib in Rheumatoid Arthritis: Post-Hoc Analyses from A Phase 3 Study Annals of the Rheumatic Diseases. 75: 1042.1-1042. DOI: 10.1136/Annrheumdis-2016-Eular.3234 |
0.344 |
|
| 2016 |
Koehn C, Dikranian A, Maniccia A, Bananis E. OP0248-PARE Understanding The Importance of A Patient's Role in The Management of Ra: Results from A Patient-Based Survey Developed by The Ra Narrative Global Advisory Panel Annals of the Rheumatic Diseases. 75: 152.2-152. DOI: 10.1136/Annrheumdis-2016-Eular.3217 |
0.307 |
|
| 2016 |
Kivitz A, Haraoui B, Kaine J, Castellano V, Bananis E, Connell C, Fan H, Takiya L. THU0174 A Safety Analysis of Tofacitinib 5 mg Twice Daily Administered as Monotherapy or in Combination with Background Conventional Synthetic Dmards in A Phase 3 Rheumatoid Arthritis Population Annals of the Rheumatic Diseases. 75: 247.2-248. DOI: 10.1136/Annrheumdis-2016-Eular.1846 |
0.343 |
|
| 2016 |
Fleischmann R, van der Heijde D, Gardiner P, Szumski A, Marshall L, Bananis E. THU0073 DAS28-CRP and DAS28-ESR Cutoffs for High Disease Activity in Rheumatoid Arthritis Are Not Interchangeable: Table 1. Annals of the Rheumatic Diseases. 75: 205.1-205. DOI: 10.1136/Annrheumdis-2016-Eular.1833 |
0.342 |
|
| 2016 |
Fleischmann R, Mease P, Schwartzman S, Hwang L, Soma K, Connell C, Takiya L, Bananis E. THU0200 Effect of Methotrexate Dose on The Efficacy of Tofacitinib: Treatment Outcomes from A Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis Annals of the Rheumatic Diseases. 75: 258.2-259. DOI: 10.1136/Annrheumdis-2016-Eular.1274 |
0.307 |
|
| 2016 |
Strand V, Kavanaugh A, Kivitz A, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen J. THU0165 Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months Annals of the Rheumatic Diseases. 75: 243.1-243. DOI: 10.1136/Annrheumdis-2016-Eular.1264 |
0.36 |
|
| 2015 |
Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. PMID 26275429 DOI: 10.1136/Annrheumdis-2014-207178 |
0.344 |
|
| 2015 |
Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials. The Journal of Rheumatology. PMID 26077401 DOI: 10.3899/Jrheum.141278 |
0.347 |
|
| 2015 |
Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index? Annals of the Rheumatic Diseases. 74: 1132-7. PMID 25143522 DOI: 10.1136/Annrheumdis-2013-204920 |
0.321 |
|
| 2015 |
Winthrop K, Lindsey S, Fan H, Wang L, Gelone D, Mendelsohn A, Bananis E, Curtis J. SAT0229 Herpes Zoster and Tofacitinib: The Risk of Concomitant Nonbiologic Therapy Annals of the Rheumatic Diseases. 74: 741.2-741. DOI: 10.1136/Annrheumdis-2015-Eular.4139 |
0.339 |
|
| 2015 |
Fleischmann R, Strand V, Wilkinson B, Kwok K, Bananis E. THU0180 Relationship Between Different Clinical Measurements and Patient-Reported Outcomes: Results from a Phase 3 Study of Tofacitinib or Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis Annals of the Rheumatic Diseases. 74: 259.2-260. DOI: 10.1136/Annrheumdis-2015-Eular.3928 |
0.339 |
|
| 2014 |
Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis. Rheumatology (Oxford, England). 53: 1984-93. PMID 24907147 DOI: 10.1093/Rheumatology/Keu235 |
0.325 |
|
| 2014 |
Pavelka K, Burgos-Vargas R, Miranda P, Guzman R, Yen JH, Izzi MA, Szekanecz Z, Tang B, Szumski A, Kotak S, Bananis E, Koenig AS, Mahgoub EY, Rahman MU. Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia International Journal of Clinical Rheumatology. 9: 415-430. DOI: 10.2217/Ijr.14.27 |
0.356 |
|
| 2013 |
Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology. 69: 729-35. PMID 23981683 DOI: 10.1016/J.Jaad.2013.07.023 |
0.305 |
|
| 2013 |
Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R. Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clinical Rheumatology. 32: 1275-81. PMID 23666316 DOI: 10.1007/S10067-013-2240-4 |
0.357 |
|
| 2013 |
Fleischmann R, Koenig AS, Szumski A, Nab H, Marshall L, Bananis E. AB0287 Efficacy of etanercept (etn) plus methotrexate (mtx) vs. disease-modifying anti-rheumatic drug (dmard) combinations with mtx in established rheumatoid arthritis (ra): duration of disease and disease severity vs. outcomes Annals of the Rheumatic Diseases. 72: A874.1-A874. DOI: 10.1136/Annrheumdis-2013-Eular.2609 |
0.323 |
|
| 2013 |
Helliwell P, FitzGerald O, Marshall L, Pedersen R, Bananis E. SAT0297 Comparison of Composite Disease Activity Scores in Psoriatic Arthritis Annals of the Rheumatic Diseases. 72: A684.1-A684. DOI: 10.1136/Annrheumdis-2013-Eular.2022 |
0.32 |
|
| 2013 |
Emery P, Szumski A, Bukowski J, Bananis E, Marshall L. SAT0071 Early Initiated Etanercept Plus Methotrexate Treatment Induces Remission in Patients with Either Moderate or Severe Rheumatoid Arthritis Annals of the Rheumatic Diseases. 72: A603.4-A604. DOI: 10.1136/Annrheumdis-2013-Eular.1797 |
0.342 |
|
| 2013 |
Baraliakos X, Koenig A, Jones H, Szumski A, Collier D, Bananis E. AB0861 Relationship between disease duration and treatment response in patients with ankylosing spondylitis (AS): Annals of the Rheumatic Diseases. 71: 687.16-687. DOI: 10.1136/Annrheumdis-2012-Eular.861 |
0.313 |
|
| 2012 |
Emery P, Kvien TK, Combe B, Freundlich B, Robertson D, Ferdousi T, Bananis E, Pedersen R, Koenig AS. Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study. Annals of the Rheumatic Diseases. 71: 989-92. PMID 22402142 DOI: 10.1136/Annrheumdis-2011-201066 |
0.325 |
|
| 2012 |
Nash P, Hall S, Bird P, Bananis E, Koenig A, Szumski A, Jones H, Kotak S, Witcombe D, Thirunavukkarasu K. Impact of etanercept-methotrexate therapy on patient-reported outcomes in moderately active rheumatoid arthritis: Australian results from the induction period of preserve trial Internal Medicine Journal. 42: 12-13. DOI: 10.1111/J.1445-5994.2012.02761.X |
0.321 |
|
| 2012 |
Szekanecz Z, Yen J, Miranda P, Szumski A, Bananis E, Kotak S, Rahman M, Tang B. PMS18 Impact of Etanercept-Methotrexate Therapy on Patient-Reported Outcomes in Moderately Active Rheumatoid Arthritis (RA) Patients of Europe, Latin America, and Asia Value in Health. 15: A674. DOI: 10.1016/J.Jval.2012.08.419 |
0.321 |
|
| 2007 |
Nath S, Bananis E, Sarkar S, Stockert RJ, Sperry AO, Murray JW, Wolkoff AW. Kif5B and Kifc1 interact and are required for motility and fission of early endocytic vesicles in mouse liver. Molecular Biology of the Cell. 18: 1839-49. PMID 17360972 DOI: 10.1091/Mbc.E06-06-0524 |
0.689 |
|
| 2006 |
Sarkar S, Bananis E, Nath S, Anwer MS, Wolkoff AW, Murray JW. PKCzeta is required for microtubule-based motility of vesicles containing the ntcp transporter. Traffic (Copenhagen, Denmark). 7: 1078-91. PMID 16734659 DOI: 10.1111/J.1600-0854.2006.00447.X |
0.678 |
|
| 2004 |
Bananis E, Nath S, Gordon K, Satir P, Stockert RJ, Murray JW, Wolkoff AW. Microtubule-dependent movement of late endocytic vesicles in vitro: requirements for Dynein and Kinesin. Molecular Biology of the Cell. 15: 3688-97. PMID 15181154 DOI: 10.1091/Mbc.E04-04-0278 |
0.641 |
|
| 2003 |
Bananis E, Murray JW, Stockert RJ, Satir P, Wolkoff AW. Regulation of early endocytic vesicle motility and fission in a reconstituted system. Journal of Cell Science. 116: 2749-61. PMID 12759371 DOI: 10.1242/Jcs.00478 |
0.633 |
|
| 2003 |
NATH S, BANANIS E, WOLKOFF A, MURRAY J. 825 Perturbation of microtubule-based trafficking of endocytosed asialoglycoprotein in living hepatocytes following disruption of endosomal PH Hepatology. 38: 559-559. DOI: 10.1016/S0270-9139(03)80867-4 |
0.546 |
|
| 2003 |
BANANIS E, MURRAY J, STOCKERT R, SATIR P, WOLKOFF A. 822 Microtubule-based bi-directional motility of early and late endosomes is mediated by distinct motor proteins Hepatology. 38: 558-558. DOI: 10.1016/S0270-9139(03)80864-9 |
0.582 |
|
| 2002 |
Murray JW, Bananis E, Wolkoff AW. Immunofluorescence microchamber technique for characterizing isolated organelles. Analytical Biochemistry. 305: 55-67. PMID 12018946 DOI: 10.1006/Abio.2002.5655 |
0.589 |
|
| 2000 |
Bananis E, Murray JW, Stockert RJ, Satir P, Wolkoff AW. Microtubule and motor-dependent endocytic vesicle sorting in vitro. The Journal of Cell Biology. 151: 179-86. PMID 11018063 DOI: 10.1083/Jcb.151.1.179 |
0.636 |
|
| 2000 |
Murray JW, Bananis E, Wolkoff AW. Reconstitution of ATP-dependent movement of endocytic vesicles along microtubules in vitro: an oscillatory bidirectional process. Molecular Biology of the Cell. 11: 419-33. PMID 10679004 DOI: 10.1091/Mbc.11.2.419 |
0.619 |
|
| Show low-probability matches. |